Docking-assisted 3D-QSAR studies on xanthones as α-glucosidase inhibitors
Tóm tắt
Recently, a series of xanthone analogues has been identified as α-glucosidase inhibitors. To provide deeper insight into the three-dimensional (3D) structural requirements for the activities of these molecules, CoMFA and CoMSIA approaches were employed on 54 xanthones to construct 3D-QSAR models. Their bioactive conformations were first investigated by docking studies and optimized by subsequent molecular dynamics (MD) simulations using the homology modeled structure of the target protein. Based on the docking/MD-determined conformers, 3D-QSAR studies generated several significant models in terms of 47 molecules as the training set. The best model (CoMSIA-SHA) yielded q
2 of 0.713, r
2 of 0.967 and F of 140.250. The robustness of the model was further externally confirmed by a test set of the remaining molecules (q
2 = 0.793, r
2 = 0.902, and k = 0.905). Contour maps provided much information for future design and optimization of new compounds with high inhibitory activities towards α-glucosidase.
Tài liệu tham khảo
International Diabetes Federation (2015) IDF Diabetes Atlas, 7th edn. International Diabetes Federation, Brussels
Yang L, Shao J, Bian Y, Wu H, Shi L, Zeng L, Li W, Dong J (2016) Prevalence of type 2 diabetes mellitus among inland residents in China (2000-2014): a meta-analysis. J Diabetes Investig 7:845–852
Joshi SR, Standl E, Tong N, Shah P, Kalra S, Rathod R (2015) Therapeutic potential of alpha-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert Opin Pharmacother 16:1959–1981
Derosa G, Maffioli P (2012) Alpha-Glucosidase inhibitors and their use in clinical practice. Arch Med Sci 8:899–906
Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, Van Weel C (2005) Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev, CD003639
Sim L, Jayakanthan K, Mohan S, Nasi R, Johnston BD, Pinto BM, Rose DR (2010) New glucosidase inhibitors from an ayurvedic herbal treatment for type 2 diabetes: structures and inhibition of human intestinal maltase-glucoamylase with compounds from Salacia reticulata. Biochemistry 49:443–451
Riaz S, Khan IU, Yar M, Ashraf M, Rehman TU, Shaukat A, Jamal SB, Duarte VC, Alves MJ (2014) Novel pyridine-2,4,6-tricarbohydrazide derivatives: design, synthesis, characterization and in vitro biological evaluation as alpha- and beta-glucosidase inhibitors. Bioorg Chem 57:148–154
Mukherjee A, Sengupta S (2013) Characterization of nimbidiol as a potent intestinal disaccharidase and glucoamylase inhibitor present in Azadirachta indica (neem) useful for the treatment of diabetes. J Enzyme Inhib Med Chem 28:900–910
Wang Q, Zhang L, Bian X, Wang Y (2014) Progress in research of alpha-glucosidase inhibitor and the structure-activity relationship. Chin J New Drugs 23:189–195
Liu Y, Zou L, Ma L, Chen WH, Wang B, Xu ZL (2006) Synthesis and pharmacological activities of xanthone derivatives as alpha-glucosidase inhibitors. Bioorg Med Chem 14:5683–5690
Liu Y, Ma L, Chen WH, Wang B, Xu ZL (2007) Synthesis of xanthone derivatives with extended pi-systems as alpha-glucosidase inhibitors: insight into the probable binding mode. Bioorg Med Chem 15:2810–2814
Liu Y, Ke Z, Cui J, Chen WH, Ma L, Wang B (2008) Synthesis, inhibitory activities, and QSAR study of xanthone derivatives as alpha-glucosidase inhibitors. Bioorg Med Chem 16:7185–7192
Li GL, He JY, Zhang A, Wan Y, Wang B, Chen WH (2011) Toward potent alpha-glucosidase inhibitors based on xanthones: a closer look into the structure-activity correlations. Eur J Med Chem 46:4050–4055
Discovery Studio 2.5.5 (2009) Accelrys, San Diego, CA
Li Z, Cai YH, Cheng YK, Lu X, Shao YX, Li X, Liu M, Liu P, Luo HB (2013) Identification of novel phosphodiesterase-4D inhibitors prescreened by molecular dynamics-augmented modeling and validated by bioassay. J Chem Inf Model 53:972–981
Li Z, Lu X, Feng LJ, Gu Y, Li X, Wu Y, Luo HB (2015) Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds. Mol BioSyst 11:115–125
Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486–501
MOE 2010 (2010) Chemical Computing Group Inc., Montreal, Quebec, Canada
Sybyl 7.3 (2006) Tripos Associates, St. Louis, MO
The PyMOL Molecular Graphics System (2002) De-Lano Scientific, San Carlos, CA
Case DA, Babin V, Berryman J, Betz RM, Cai Q, Cerutti DS, et al (2014) Amber 14. University of California, San Francisco
Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR et al (2004) Gaussian 03, Gaussian Inc., Wallingford, CT
Wang J, Wang W, Kollman PA, Case DA (2001) Antechamber: an accessory software package for molecular mechanical calculations. J Am Chem Soc 222:U403
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14(33-8):27–28
Zheng XH, Shao YX, Li Z, Liu M, Bu X, Luo HB, Hu X (2012) Quantitative structure-retention relationship of curcumin and its analogues. J Sep Sci 35:505–512
Lee Y, Kim S, Kim JY, Arooj M, Kim S, Hwang S, Kim BW, Park KH, Lee KW (2014) Binding mode analyses and pharmacophore model development for stilbene derivatives as a novel and competitive class of alpha-glucosidase inhibitors. PLoS One 9:e85827
Bharatham K, Bharatham N, Park KH, Lee KW (2008) Binding mode analyses and pharmacophore model development for sulfonamide chalcone derivatives, a new class of alpha-glucosidase inhibitors. J Mol Graph Model 26:1202–1212
Park H, Hwang KY, Oh KH, Kim YH, Lee JY, Kim K (2008) Discovery of novel alpha-glucosidase inhibitors based on the virtual screening with the homology-modeled protein structure. Bioorg Med Chem 16:284–292
Ferreira SB, Sodero AC, Cardoso MF, Lima ES, Kaiser CR, Silva FP, Ferreira VF (2010) Synthesis, biological activity, and molecular modeling studies of 1H-1,2,3-triazole derivatives of carbohydrates as alpha-glucosidases inhibitors. J Med Chem 53:2364–2375
Yamamoto K, Miyake H, Kusunoki M, Osaki S (2010) Crystal structures of isomaltase from Saccharomyces cerevisiae and in complex with its competitive inhibitor maltose. FEBS J 277:4205–4214